Info

Immtech Pharmaceuticals, Inc. is focused on global opportunities in the healthcare sector. The Company’s subsidiaries include Immtech Hong Kong Limited, Immtech Therapeutics Limited, Super Insight Limited and Immtech Life Science Limited. During the fiscal year ended March 31, 2008 (fiscal 2008), its drug development program for pafuramidine was discontinued due to findings of renal and liver adverse events among participants in its study of healthy volunteers conducted in South Africa. This clinical trial had been initiated to provide safety data in support of the African sleeping sickness and pneumocystis pneumonia indications. It was halted in December 2007, after several subjects developed abnormal liver function (clinical hold). The program was formally discontinued in February 2008, when five subjects in the same study developed renal abnormalities that required medical intervention and hospitalization.(Source: 10-K)